Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing by Juliano, J. J. et al.
Exposing malaria in-host diversity and estimating
population diversity by capture-recapture using
massively parallel pyrosequencing
Jonathan J. Julianoa,1, Kimberly Porterb, Victor Mwapasac, Rithy Semd, William O. Rogerse, Frédéric Arieyf,
Chansuda Wongsrichanalaie, Andrew Readg,h, and Steven R. Meshnickb
aDivision of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC 27514; bDepartment of Epidemiology, Gillings School of
Global Public Health, University of North Carolina, Chapel Hill, NC 27514; cDepartment of Community Health, University of Malawi College of Medicine,
Blantyre 3, Malawi; dThe National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia; eNaval Medical Research Unit No. 2,
Pearl Harbor, HI 96860; fInstitut Pasteur du Cambodge, Phnom Penh, Cambodia; gCentre for Infectious Disease Dynamics, Departments of Biology and
Entomology, Penn State University, University Park, PA 16802; and hFogarty International Center, National Institutes of Health, Bethesda, MD 20892
Edited by Thomas E. Wellems, National Institutes of Health, Bethesda, MD, and approved October 12, 2010 (received for review May 20, 2010)
Malaria infections commonly contain multiple genetically distinct
variants.Mathematical andanimalmodels suggest that interactions
among these variants have a profound impact on the emergence of
drug resistance. However, methods currently used for quantifying
parasite diversity in individual infections are insensitive to low-
abundance variants and are not quantitative for variant population
sizes. To more completely describe the in-host complexity and
ecology of malaria infections, we used massively parallel pyrose-
quencing to characterize malaria parasite diversity in the infections
of a group of patients. By individually sequencing single strands of
DNA in a complex mixture, this technique can quantify uncommon
variants in mixed infections. The in-host diversity revealed by this
method far exceeded that described by currently recommended
genotyping methods, with as many as sixfold more variants per
infection. In addition, in paired pre- and posttreatment samples, we
show a complex milieu of parasites, including variants likely up-
selected and down-selected by drug therapy. As with all surveys of
diversity, sampling limitations prevent full discovery and differ-
ences in samplingeffort can confound comparisons amongsamples,
hosts, and populations. Here, we used ecological approaches of
species accumulation curves and capture-recapture to estimate the
number of variants we failed to detect in the population, and show
that these methods enable comparisons of diversity before and
after treatment, as well as between malaria populations. The
combination of ecological statistics and massively parallel pyrose-
quencing provides a powerful tool for studying the evolution of
drug resistance and the in-host ecology of malaria infections.
Plasmodium falciparum | next generation sequencing
The evolution of drug-resistant malaria represents an immensethreat to global health. With nearly 40% of the global pop-
ulation at risk, 300 to 660 million cases of Plasmodium falciparum
malaria occur annually, causing an estimated 1 million deaths (1).
The evolutionary selection of malaria occurs both within in-
dividual hosts and within populations. Whereas the later has been
extensively studied, the former has mostly been the realm of the-
oretical studies in humans and experimental models in animals
and in vitro (2–8). An understanding of the in-host evolutionary
selection of malaria parasites is critical to understanding the
emergence of drug resistance (7).
Most patients with P. falciparum infections are infected with
multiple genetically distinct parasite variants (also called clones,
genotypes, or clonal lineages). This situation could be a result of
multiple infectious mosquito bites, or bites from mosquitoes in-
fected with multiple parasite variants (9). In areas of low trans-
mission, such as in Asia or Latin America, patients may have
infections with as few as a single variant or as many as six variants
(10). In areas of high transmission, such as in sub-Saharan Africa,
more than 10 variants can be routinely detected in an individual
(11, 12). Thus, within-host selection among these variants, espe-
cially in areas of high transmission, is likely to play an important
role in parasite evolution.
Existing methods to measure parasite heterogeneity have been
shown tomissmany variants within an individual (13, 14). Themost
commonmethod uses nestedPCR (nPCR)with gel electrophoresis
to detect polymorphisms in the variable surface antigensmerozoite
surface protein 1 (msp1), merozoite surface protein 2 (msp2), and
glutamine rich protein (glurp) (15). However, nPCR with gel elec-
trophoresis detects only size polymorphisms and cannot detect
sequence polymorphisms. Furthermore, it has been shown that
nPCR methods are insensitive to low-abundance variants (3, 16).
Last, the method is not quantitative for relative population sizes of
different variants. Because of these limitations, it has not been
possible to study within-host evolution of human malaria parasites
by using these methods. To study the competition and selection
between variants in a mixed malaria infection, new tools are re-
quired that are sensitive to minority populations and quanti-
tative for relative parasite population sizes in the host (17). Next-
generation sequencing techniques, such as massively parallel
pyrosequencing (MPP), provide the increased resolution of in-host
diversity necessary for more thorough ecological studies of in-
host selection.
In this study, we investigated the use of MPP to study the
diversity of P. falciparum in individuals and estimate the parasite
population diversity in a malaria endemic community. More than
90 thousand partial P. falciparum msp1 block 2 and msp2 central
variable repeat sequences were obtained from patients living in
a region of very high transmission (Malawi) and a region of low
transmission (Cambodia). These are the regions amplified by
World Health Organization (WHO)-recommended genotyping
protocols (15). Details about the genetic structure of these genes
have been extensively reviewed (15, 18–21). Our objectives were
to: (i) compare the number of variants detected (or multiplicity
of infection) by deep sequencing and nPCR genotyping methods
at each gene site, (ii) estimate the effects of increasing depth of
sequencing on estimates of diversity, (iii) follow the changes in
variant number and population sizes longitudinally in patients,
and (iv) use capture-recapture methods to estimate the total
genetic diversity in a community. In addition, we deep sequenced
the dhfr gene from patients to show that 454 sequencing can
provide information on drug resistance haplotypes, detect novel
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SNPs in drug resistance genes, and estimate the error-free se-
quencing rate of 454 sequencing in the AT-rich malaria genome.
Results
Determining the Sequencing Error Rate. The error free rate was
determined to be 99.1%, a slightly higher error rate than has
previously been reported for 454 sequencing (22). This likely
results in part from the highly AT-rich genome of the malaria
parasite. The specific methods and types of errors are summa-
rized in SI Results.
In-Host Parasite Diversity Revealed by MPP. In total, pyrosequenc-
ing provided 115,518 sequence reads in the sections of the plate
dedicated to msp1 and msp2. A total of 91,645 reads (79%)
mapped to the malaria genome. Of these, 44,590 (39%) were
used to build the consensus sequences for the amplicons of in-
dividual variants in the patients. The large reduction in total
usable sequencing reads in part reflects the exclusion of short
reads from building the consensus sequences and the exclusion
of sequences containing an incomplete barcode or forward
primer sequences (Materials and Methods). The average numbers
of reads used per locus per patient to create the unique con-
sensus sequences for variants in a sample were 1,371 (SD, 787)
from Malawi and 2,144 (SD, 2,346) from Cambodia. The re-
petitive sequence alignment analysis used to create these con-
sensus sequences served the purpose of overcoming sequencing
errors. Each resulting unique consensus sequence was consid-
ered a variant. The number of variants detected by nPCR and
MPP are summarized in Table 1. MPP detected as many as
sixfold more variants than nPCR with gel electrophoresis.
Among the Malawian samples, MPP detected on average of 5.0
more msp2 variants per individual than nPCR with gel electro-
phoresis [95% confidence interval (CI), 2.1–7.9] and 4.8 more
msp1 variants per individual than nPCR with gel electrophoresis
(95% CI, 2.4–7.1). Among the Cambodian samples, 3.3 (95% CI,
0.9–5.6) more msp2 and 2.0 (95% CI, −1.9 to 5.9) more msp1
variants were detected by MPP relative to nPCR with gel elec-
trophoresis. Additional information about the comparison of
MPP versus other genotyping methods is described in SI Results.
Among nine successfully sequenced Malawian patient samples
at msp2, a total of 62 distinct variants were detected (GenBank
accession nos. HM153086–HM153147). This represented 52
unique variants, with the remaining 10 shared between samples.
BlastN analysis of these 52 variants showed five (10%) with
a perfect sequence match to previously reportedmsp2 sequences.
The average variant consensus sequence length was 245 bp (range,
153–411 bp). Similarly, among the 11 Malawian samples suc-
cessfully sequenced at msp1, a total of 77 variants were detected
(GenBank accession nos. HM153166–HM153242). This repre-
sented 63 unique variants (14 shared). Of these 63 variants, BlastN
analysis showed nine (14%) with a perfect sequence match to
previously reported msp1 sequences. The average consensus se-
quence length was 298 bp (range, 178–397 bp). Both patients with
paired initial and recurrent parasitemias from Cambodia were
successfully sequenced at both msp1 and msp2. At msp2, 17 var-
iants were detected (GenBank accession nos. HM153080–
HM153164) that contained 16 unique variants (one shared). Six of
these variants (38%) had exact sequence matches to previously
reported sequences by BlastN analysis. The average variant con-
sensus sequence length was 254 bp (range, 165–365 bp). Atmsp1,
14 variants were detected (GenBank accession nos. HM153243–
HM153256), which contained 12 unique variants (two shared).
Five of these variants (42%) had exact sequence matches to pre-
viously reported sequences by BlastN analysis. The average vari-
ant consensus sequence length was 305 bp (range, 230–331 bp).
Effects of Sampling Effort on Variant Discovery. In general, the
number of entities discovered is highly dependent on sampling
effort. In the current context, this means that, as more sequences
are analyzed, the number of variants discovered will increase.
This is clear in our data (Fig. 1A), but it is also equally clear that
some samples contain fewer variants than others, and the ques-
tion arises whether more sequencing effort would have led to
further discovery, or if we are close to a diversity asymptote. This
issue also informs decisions about the depth of sequencing re-
quired in such analyses. In the current analyses, depth was de-
termined by the amount of input DNA used to make the
sequencing library. The curves in Fig. 1A are directly analogous to
“species accumulation” curves in ecology (23). These can be used
to estimate individual-based rarefaction curves, which estimate
the number of variants that would have been observed had we
made any small number of reads (24, 25). It is possible to estimate
CIs for such curves, which enables comparisons of diversity even
when there are differences in sampling effort (24, 25). These are
shown for several of our patient samples in Fig. 1 B–D. Note that
the curves plotted in Fig. 1A are single realizations of a range of
variant accumulation curves that would be produced by repeated
deep resequencing of the same blood samples; the smoothed
rarefaction curves represent the expected variant richness values
for the corresponding accumulation curves.
Several conclusions emerge from these analyses. First, there is
evidence that we have fully discovered all the msp2 diversity in
some samples [e.g., the posttreatment sample in patient 1/014
(Fig. 1B), in which there are four clones], whereas in other
samples there is little evidence that we are nearing an asymptote,
implying that even deeper pyrosequencing is needed to estimate
the diversity present [e.g., the pretreatment sample of patient 1/
014 (Fig. 1B) and posttreatment samples of patient 1/009 (Fig.
1C)]. An implication of this is that there is no simple rule con-
cerning the depth of pyrosequencing required to estimate the
number of variants present—in effect, we went unnecessarily
deep for two samples [1/014 III (Fig. 1B) and 2/044 I (Fig. 1D)],
whereas even deeper sequencing would have likely been in-
formative in other cases [1/014 I (Fig. 1B), 1/009 I and II (Fig.
1C), and possibly even sample 2/041 (Fig. 1D)]. This means that,
for the latter samples, the numbers given in Table 1 for the msp2
variants are minima, whereas we conclude with high certainty
that the numbers given for the former samples are sound esti-
mates of the actual number present. These findings also show
that the depth of sequencing can be varied based upon the goals
of the user. As a significant proportion of diversity is detected by
250 sequencing reads in most samples, if a purpose does not
Table 1. Comparison of the number of variants detected by












2/041 I 3 8 1,475 1 11 2,036
2/041 III 2 4 1,333 2 3 3,307
1/021 I 1 3 1,215 ND ND ND
2/007 I 3 8 1,193 1 6 185
1/009 I 3 16 1,191 3 12 1,222
1/009 II 3 11 2,159 3 11 932
2/044 I 1 2 634 1 3 288
1/014 I 3 7 1,135 2 10 2,021
1/014 II 1 3 339 2 2 2,464
1/014 III 1 4 943 2 4 2,126
2/040 I 4 11 1,238 ND ND ND
Cambodia
46 initial 2 2 113 1 3 1,058
46 recurrent 2 2 702 1 3 1,278
84 initial 1 6 1,259 1 5 2,955
84 recurrent 1 4 7,461 1 6 2,328
ND, not detected.












require the exhaustive measurement of variants within a single
sample, higher levels of multiplexing could be used to decrease
the sequencing costs.
Second, the approach makes possible the comparison of di-
versity among samples. Such comparisons are straight forward
when the depth of sequencing is similar. For patient 1/014, for
example, there was similar sampling effort before and after
treatment (Fig. 1B), and it is clear that diversity in the second
sample was substantially lower (for clones compared with at least
10 before treatment). For patient 1/009, however, we obtained
300 more reads from the pretreatment sample, but despite this
extra effort, there is no evidence that the variant richness before
and after treatment differs: for any level of sampling effort, the
estimates of diversity are similar, and the CIs overlap [Fig. 1C].
We can also be confident that the number of msp2 variants in
patient 2/044 was substantially less than that in patient 2/041
(three vs. at least 10; Fig. 1D), even though the depth of se-
quencing varied sevenfold between the two samples.
To summarize, there is evidence that variant diversity differs
significantly among patients, that diversity was reduced after
drug treatment in one patient (Fig. 1B) but not in another (Fig.
1C), and that we can estimate with considerable confidence how
many clones are present in some hosts, but not in others. The
degree of confidence is poorly correlated with sampling effort.
Determining the Effect of Treatment on In-Host Variant Populations.
For two patients, we had MPP data before and after sulfadoxine–
pyrimethamine treatment. Fig. 2A shows each of the variants
present before and after treatment in a single patient (1/009, the
patient also shown in Fig. 1C). The size of each variant’s bubble
is proportional to the population size of that variant (no. of se-
quencing reads used to build the consensus sequence of that
variant/total no. of sequencing reads used to build the consensus
sequences of all variants in the sample). In this patient, the pre-
and posttreatment samples shared four variants. In addition,
both the pre- and posttreatment samples have a large number of
unique variants. Fig. 2B shows samples from a second patient (1/
014) who had two recurrent episodes of parasitemia. In each
case, the recurrent parasitemia did not contain a shared geno-
type with the previous infection. However, each sample did
contain a shared genotype with other patients in our study. The
initial treatment caused a significant decrease in complexity of
infection in the second infection.
Determination of the Community-Wide Population Diversity. We
used a capture-recapture technique to estimate the total number
of variants in the parasite population at our Malawi site. Capture-
recapture methods were originally developed to enumerate dif-
ficult to measure wildlife populations although have been adapted
for use in epidemiological studies. When we limited the analysis
to variants identified in initial parasitemias, we identified 48
unique variants of msp1 and 41 unique variants of msp2. Using
estimators developed by Chao (26) that are specifically for sparse
data and allow heterogeneous capture probabilities, we estimated
that the total number of variants formsp1 was 356 (95% CI, 143–



































































Fig. 1. msp2 genotype discovery curves. These figures show genotype discovery curves and rarefaction curves for several patient samples. The genotype
discovery curves are generated by plotting the number of unique sequence variants in a sample (y axis) against the rank order of sequences reads generated
(x axis). Therefore, the x axis illustrates the cumulative number of sequences determined for a sample at a given site (number of sequence reads or fold
coverage of the site), which are ordered by the sequential well number of the 454 picotiter plate, which reflects increasing sampling effort. (A) Number of
msp2 variants discovered with increasing sequencing effort in six samples. Patient codes and sample numbers cross-reference with those in Table 1. As
expected, the number of variants discovered is a function of sequencing effort, but for a given effort, some samples contain more variants than others. For six
samples, expected variant richness (rarefaction), curves (thick lines), and 95% CI (thin lines) for (B) patient 1/014 before and after drug treatment [light blue
(Upper) and brown (Lower) lines, respectively; samples 1 and 3], (C) patient 1/009 before and after drug treatment (pink and dark blue lines, respectively;
samples 1 and 2), and (D) msp2 diversity in two different patients [2/041 I and 2/044 I, black (Upper) and red (Lower) lines, respectively].
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Discussion
For more than 30 y, it has been clear that falciparum malaria
infections are polyclonal (27, 28). However, in the past several
years, it has been suggested that the amount of previous reports of
diversity have described only the “tip of the iceberg” (10, 11, 16).
Here we expose the extent of in-host diversity by using MPP to
quantify and identify rare variants in polyclonal malaria infections
in a high-throughput manner. In addition, the ability to accurately
and quantitatively describe the in-host population of malaria
parasite variants is critical for understanding the ecological inter-
actions between these variants in a single infection. Mousemodels
suggest important ecologic interactions between variants (5, 8).
However, because of the lack of appropriate tools, these issues
have not been extensively studied in human populations.A body of
correlational epidemiological evidence is consistent with crowding
effects [“competitive interactions” (7, 29)] in human malaria
infections, and some patterns of drug resistance inAfrica aremore
readily explained by invoking differences in parasite fitness as
a result of competition (5, 6, 30–33). Recrudescences consistent
with competitive release, when one variant performs better after
removal of its competitors by chemotherapy, were recently ob-
served in human populations (34). If these interactions are wide-
spread in human parasite populations, the information about
interactions inmixed populations could significantly assist malaria
control efforts. The experiments we report here are the first steps
in developing the tools necessary to understand the dynamics of
parasites within hosts and the effect of selective pressures in
mixed populations.
The limitations of currently recommended WHO genotyping
procedures to exhaustively detect variants inmixed infections have
been extensively reviewed (13). As a result of these limitations,
multiple investigators have suggested alternative methods that
potentially increase the relative diversity detected (10–12, 20).
MPP represents a powerful approach to detect in-host diversity of
malaria infections. The key breakthrough of the MPP sequencing
platform is the ability to sequence single strands of DNA from
a complex mixture of DNA. This allows the identification of rare
variants as well as the quantification of variant population sizes in
mixed infections. In addition, compared with other next-genera-
tion sequencing methods, such as Illumina/Solexa, read length is
significantly longer, allowing for larger variable regions to be
studied. This is the power of 454 sequencing. HIV researchers
were among the first infectious disease researchers to use this
technology to describe in-host diversity, and an extensive literature
is developing.Multiple reports have appliedMPP to the detection
and characterization of rare drug-resistant variants (35–38). This
technique has also been used to detect low-frequency pretherapy
chemokine (CXC motif) receptor 4 (39). In addition, MPP has
been used to address questions on the dynamics of HIV quasis-
pecies in response to selective pressure. The ability of MPP to
detect minority variants and to quantitate the relative variant
frequencies in an infection makes it an appropriate tool for
studying the in-host ecology of malaria. These data represent an
initial evaluation of in-host diversity, and additional studies to
refine data analysis methods and estimate reproducibility param-
eters are clearly required.
We found that MPP, on average, detected substantially more
variants per infection than the currently recommended WHO
methods.More importantly, we foundahighly complexmilieuwhen
looking at paired patient samples (i.e., Fig. 2). In Malawi, paired
initial and recurrent parasitemia samples contained some shared
variants suggestive of recrudescence. However, the majority of
variants in the recurrent parasitemia were different. This suggests
the potential of a significant amount of reinfection occurring in
thesepatients.The averagedurationbetweenpaired sampleswas 28
days.Another possibility is thatMPPgenotyping still failed to detect
all variants within the sample, as is suggested by our genotype dis-
covery analysis (Fig. 1). An additional potential limitation is that
samples from a single initial parasitemia blood spot were used and
additional variants could have been sequestered out of circulation.
In the setting of a low transmission intensity in Cambodia,
MPP again, on average, detected more variants than described
by nested PCR. These paired patient samples had previously
been genotyped by nPCR with gel electrophoresis, msp1 HTA,
and msp2 HTA as part of the assessment of misclassification in
antimalarial clinical trials (10, 40). In the original clinical trial,
both these patients were considered to represent reinfections by
nPCR with gel electrophoresis (10, 40). The MPP data con-
firmed the findings of our previous study: that by current prac-
tices, patient 46 should be classified as a case of recrudescence
(i.e., one shared allele at msp1 and msp2) and patient 84 should
be classified as a case of reinfection (i.e., one shared allele at
msp1 and no shared msp2 allele).
These findings are not wholly unexpected, as previous studies
that sequenced variants from mixed infections have shown more
complexity than detected by nested PCR. For example,Mayengue
et al. reported that three variant allele sizes detected by nested
PCR actually contained 23 variants detected by sequencing (41).
However, these reports required very labor-intensive methods,
and newer high-throughput sequencing tools like MPP will allow
for this type of analysis on a larger scale.
Fig. 2. msp2 variant dynamics between longitudinal patient samples from
Malawi. (A) Change in variant population in a pre- and posttreatment
sample pair (1/009I and 1/009 II). The green and blue circles represent unique
variants detected in the initial parasitemia and recurrent parasitemias, re-
spectively. The brown, orange, yellow, and red circles represent population
sizes of variants that are shared between the two samples. (B) Genotypes of
three infections in patient 1/014. In each case, treatment appears to have
cleared all of the genotypes as none of the samples contained a shared
genotype within the same patient. However, all of the samples did contain
a genotype identified in other patients in the study. Of note, there was
a significant reduction in the complexity of infection between the first and
second infection with sulfadoxine–pyrimethamine treatment.












One concern for the use of amplicon protocols in MPP is the
potential for recombination occurring during amplification cre-
ating false variants, especially for high-diversity samples requiring
multiple PCR cycles (42). In fact, recombination during PCR of
msp1 has been known for some time, with ratios (recombinant
haplotype to parent haplotype) of 1.8% to 28.6% in an nPCR
protocol reported by Tanabe et al. (18, 43). However, the ampli-
con they evaluated contained block 2 to 6 of msp1 and was sig-
nificantly larger (approximately 1,100 bp) than the one we
evaluated. The use of a much smaller fragment (approximately
300 bp) will, to a certain, extent limit the amount of recombination
seen. In addition, the prolonged extension times used (1.5 min for
a 300-bp fragment) will help reduce recombination. We have not
directly assessed recombination rates for this project. However,
a review of the consensus sequences for the variants did not show
any blatant recombination events (i.e., a 3′ end sequence similar in
one clone to a 5′ in another). Further mixing studies of control
DNA are required to evaluate the extent of recombination and
PCR amplification bias of different-sized fragments occurring
during amplification of msp1 and msp2 for MPP. In addition,
other approaches to minimize the effect of recombination should
be evaluated, such as decreasing the number of cycles if adequate
starting material is available (we were unable to do this working
from dried blood spots) or more advanced techniques such as
emulsion PCR or use of improved proof-reading enzymes for the
initial amplification (42, 44).
Molecular techniques with improved ability to distinguish be-
tween variants have recently shown highly diverse parasite pop-
ulations in areas of high transmission, in particular using themsp2
loci (45).However, the parasite variants observed in patients likely
make up only a sample of circulating variants, as it is impossible
to exhaustively sample the parasites circulating in a population.
Capture-recapture is a method developed for wildlife ecological
studies, which has since been adapted to epidemiological studies,
to estimate population size in cases in which it was impossible to
measure the entire population being studied. In this method, the
extent of incomplete ascertainment is estimated by using in-
formation from overlapping lists of samples from distinct sources
(i.e., variants shared between two independent people) (46).
Using each individual patient as a “source,” we conducted a
capture-recapture evaluation to estimate the total number of
variants in the population inMepemba andMadziabango,Malawi.
The accuracy of this type of assessment is dependent on several
factors: (i) independence of observations, (ii) accuracy of data,
(iii) equal chance of individual variants being captured, and (iv)
a closed population. In an attempt to control for the first factor,
only initial parasitemias were used to prevent the issue of de-
pendence in the form of recrudescences. In addition, by including
only variants identified in initial parasitemias, we simplified the
analysis and reduced bias from capture probabilities possibly
varying by time and no definitive way of classifying parasites found
in recurrent parasitemias as reinfections or recrudescences. As
MPP provides determination of variants to the sequence level,
accuracy was assumed to be high. However, as there is a PCR
amplification step for the procedure, this could introduce bias
by the failure to amplify certain variants. Traditional capture-
recapture methods assume that all individuals in the population
(in this case, all parasite variants) have the same probability of
being captured (i.e., “catchability”). The estimates we used were
robust to violation of this assumption, which is important in this
context because the underlying distribution of genetic variants in
the population is not uniform. The fourth factor, a closed pop-
ulation, is potentially an issue for estimates of malaria diversity.
This estimate of diversity is partially limited by a likely un-
derestimate of variants from the sequencing analysis and by large
CIs from the small sample sizes. However, it is a useful example of
this method and demonstrates the potential for a significant un-
measured amount of diversity in a population.
A high degree of genetic variability inmsp2 and msp1 has been
previously reported in Africa. For example, Schoepflin et al.
reported 76msp2 variants and 29msp1 variants in the Kilombero
district of Tanzania by using a sensitive capillary electrophoresis
method (45). However, these estimates are dependent on the
ability of the survey to capture all the circulating variants. Similar
to these previous reports, we found a high level of genetic diversity
at msp2 [measured, 41 variants; estimated total, 421 (95% CI,
140–1,505)]. We also found equally high genetic diversity atmsp1
[measured, 48 variants; estimated total, 356 (95%CI, 143–1,043)].
Because of the small number of patients, the estimates of pop-
ulation size have wide CIs and, as with any analysis that requires
currently untestable assumptions, one must appreciate that there
is uncertainty about the estimate. Still, our findings suggest that
genetic diversity can be greatly underestimated without account-
ing for additional unobserved variants.
In this study, we expose the complexity of malaria infections by
using MPP. Falciparum malaria infections contain more diversity
than has previously been suggested, raising concerns about how
we have studied parasite diversity in the past. In addition, we
propose the use of classic ecological tools to improve our esti-
mates of malaria diversity in patients as well as in a community
despite limited sampling. These new tools will empower the
study of the evolutionary and ecological factors involved in the
spread of drug resistance.
Materials and Methods
Human Subjects.We studied parasites from thefilter paper blood spots of nine
patients that were collected during two previously completed studies. Seven
womenwhotookpart inatrial of intermittentpreventivemalaria treatment in
Mpemba andMadziabango,Malawi, provided 11 samples during parasitemic
episodes (47). Two patients from an in vivo efficacy trial of artesunate–
mefloquine in Chumkiri, Cambodia, provided initial and recurrent para-
sitemia samples (40). The institutional review boards of the University of
North Carolina, the Malawi College of Medicine, the Cambodian Ministry of
Health, andNavalMedical ResearchUnit No. 2 approved these studies (40, 47).
Nested PCR Genotyping of msp1 and msp2. Nested PCR followed previously
published protocols as described in SI Materials and Methods.
Overview of Variant Genotyping by MPP. Full details of the MPP procedures
and data analysis are given in SI Materials and Methods. In brief, PCR
products for 454 sequencing were prepared using primers specific for three
regions of the of the malaria genome: (i) the block 2 region of msp1, (ii) the
central variable region of msp2, and (iii) the segment of dhfr containing aa
51, 59, and 108. For each region, and for each patient sample, this generates
a library of amplicons thought to be representative of the parasite pop-
ulation [based on previous reports in the HIV literature (48)]. Thus, we might
have 2,000 amplicons from a patient sample for the defined region of msp2.
These 2,000 amplicons are then individually sequenced using the 454, giving
msp2 sequences for as many as 2,000 individual strands of amplicon DNA in
that sample. The issue then is to determine from these sequences how many
msp2 variants are present among those 2,000 parasites.
To ensure our measured variation was not a result of sequencing error, we
developed consensus sequences for each variant. When identifying unique
variants, we elected to prioritize large (>6 bp) insertions and deletions and
allelic families over SNP differences. This was mediated by: (i) a desire to
conservatively estimate diversity by not over-calling variants created as a re-
sult of recombination or PCR error, (ii) the results of a coincident analysis of
error showing high rates of single nucleotide indels and occasional SNPs
(given the average read length of just less than 300 bp and an error-free
sequencing rate of 99.1%, we would expect fewer than three errors in that
read length), and (iii) the unique features of pyrosequencing a highly rich AT
genome, which requires the modification and development of new bio-
informatic tools for analysis that are still under development. In total, our
adopted approach would predictably underestimate the diversity of samples.
Briefly, the analysis occurred in a two-step format: (i) evaluation for length
polymorphisms at least 6 bp followed by (ii) an evaluation of sequence ho-
mology. First, for a given patient, all sequences for a single allele were aligned
using ClustalW. These initial alignments were visually divided into groups of
sequences based on the allelic family of the repeat and the presence of indels
of at least 6 bp. Sequences within each group were then separately realigned.
Occasionally, these realignments revealed the presence of two groups within
the initial group based on the presence of an additional indel of at least 6 bp,
typically at the 3′ end of the sequence. In this case, the group was again
subdivided and the sequences within the subgroups realigned. After that, the
20142 | www.pnas.org/cgi/doi/10.1073/pnas.1007068107 Juliano et al.
alignments based on length polymorphism were then evaluated for sequence
homology. Subgroups were created again if sequences varied by approxi-
mately 3% (approximately 9 bp in 300 bp). These final alignments were then
used to build the consensus sequence, which defined each variant. The gener-
ated consensus sequence was then evaluated by the investigator for the pres-
ence of ambiguous nucleotides (either SNPs or single BP indels), which were
called by a simple approach of “majority rule” to determine the final consensus
sequence that defineda variant. The consensus sequences definingeach variant
were then checked for correct translation and then aligned to confirm that all
variantswithinapatient samplewereuniqueanddiffered fromeachotherbyat
least 5 bp as SNPs or at least 3 bp for indels. The number of variants detecteddid
not significantly change if the number of unique SNPs required to define
a variant was increased to eight or the size of the required insertion/deletion
was increased to at least 6 bp. These consensus sequences were then compared
with other previously reported sequences at the allele using BlastN.Multiplicity
of infection for an given blood sample was then calculated separately for each
genomic region, based on the number of unique variants at each region
detected in the patient sample.
Variant Accumulation Curves. Rarefaction curves were calculated using Esti-
mateS (http://viceroy.eeb.uconn.edu/estimates) using individual-based curves
(sampling without replacement) (24) based on the Michaelis–Menten models
(49). We note that the impact on the shape of species-accumulation curves of
different community structures is an area of active research (50); with the data
at hand (six samples), we are unable to satisfactorily explore this issue.
Estimating Population Sizes of msp1 and msp2 Variants. We treated each in-
dividual patient as a source able to capture individual parasite variants. We
calculated estimates of the total number of msp1 and msp2 variants using
estimators developed by Chao (26).
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